论文部分内容阅读
过去一年中,整个华尔街股市生物技术股的市值已经翻番,达到3000多亿美元,纳斯达克生物技术类指数在过去的一年半中上升了312％,标准普尔生物技术类指数从去年第四季度开始攀升,至今升幅已达100％,部分个股的表现更令人侧目:MED(Medarex)主营单克隆抗体药物,用于治疗癌症及其它严重疾病,2月下旬,该公司宣布其癌症药物进入实验后期,虽然尚末经联邦药品监管局批准,疗效也未得到最终认可,公司股价已由12月初的11美元飙升
Over the past year, the market capitalization of entire Wall Street stock biotech shares has doubled to more than $ 300 billion, and the Nasdaq Biotech Index has risen 312% in the past year and a half. The S & P Biotech Index, as of last year The fourth quarter began to climb, has soared 100%, some stocks even more impressive: MED (Medarex) the main monoclonal antibody drugs for the treatment of cancer and other serious diseases, in late February, the company announced its Cancer drugs into the later stages of the experiment, although not approved by the Federal Drug Administration, the efficacy has not been finally recognized, the company's stock price soared from 11 early December soared